EXCEL-Punjabi: A Culturally Tailored Exercise Oncology Pilot Feasibility Intervention (EXCEL-Punjabi)

June 8, 2026 updated by: University of Calgary

EXCEL-Punjabi: Tailored Exercise Oncology for the South Asian Population

The goal of this pilot feasibility study is to explore the feasibility and exploratory effects of a culturally-tailored exercise oncology intervention in Punjabi-speaking individuals of South Asian heritage and their support persons. The main questions it aims to answer are:

  1. What is the feasibility and acceptability of the EXCEL-Punjabi intervention?
  2. What are the exploratory effects (i.e., psychosocial and physical changes) before and after program delivery?

Participants will take part in a 12-week exercise oncology intervention consisting of twice weekly hour long multimodal circuit-based exercise sessions. They will also complete questionnaires and functional fitness assessments pre- and post- intervention.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Genesis Centre Calgary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Punjabi-speaking
  • Self-identified as being of South Asian heritage
  • over the age of 18
  • pre-, post-, or currently receiving cancer treatment or a support person of an individual living with and beyond cancer
  • cleared to participate in, at minimum, mild intensity exercise by a Clinical Exercise Physiologist
  • Able to provide informed consent

Exclusion Criteria:

  • under the age of 18
  • not cleared to exercise by a Clinical Exercise Physiologist

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: EXCEL-Punjabi
Culturally Tailored Exercise Oncology Intervention
Behavioral: EXCEL-Punjabi
Culturally Tailored Exercise Oncology Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement Completion
Time Frame: Baseline to the end of the intervention (12 weeks)
Participants who completed all pre- and post- questionnaires and functional assessments
Baseline to the end of the intervention (12 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Referrals
Time Frame: Baseline to end of intervention (12 weeks)
Number of participants referred to intervention
Baseline to end of intervention (12 weeks)
Consented
Time Frame: Recruitment to end of intervention (12 weeks)
Number of participants who consented to participate in the intervention
Recruitment to end of intervention (12 weeks)
Enrolled
Time Frame: Baseline (week 0)
Number of participants who enrolled (i.e. completed baseline assessments)
Baseline (week 0)
Attendance
Time Frame: Baseline to end of intervention (12 weeks)
Intervention Attendance
Baseline to end of intervention (12 weeks)
Adverse Events
Time Frame: Baseline to end of intervention (12 weeks)
Using the standardized Common Terminology Criteria for Adverse Events Version 6.0
Baseline to end of intervention (12 weeks)
Time Required to Deliver and Implement Intervention
Time Frame: From recruitment to end of intervention (12 weeks)
Time requirement to deliver intervention
From recruitment to end of intervention (12 weeks)
Physical Activity Level
Time Frame: Baseline to end of intervention (12 weeks)
The Godin Leisure Time Exercise Questionnaire is used to determine subjective levels of physical activity in each participant. Participants report how many times per week they partake in mild, moderate, and/or strenuous exercise. Higher scores indicate a more physically active lifestyle.
Baseline to end of intervention (12 weeks)
Cancer related symptoms
Time Frame: Baseline to end of intervention (12 weeks)
Change in Edmonton Symptom Assessment Scale - revised: cancer. Scale is from 0-10, where 0 means the symptom is absent and 10 means the worst possible severity of the symptom is being experienced.
Baseline to end of intervention (12 weeks)
Health Related Quality of Life
Time Frame: Baseline to end of intervention (12 weeks)
Change in EuroQual - 5Dimensions (EQ-5D) tool - first section is a questionnaire; last section uses a scale from 0-100, where 0 means the worst health imaginable and 100 means the best health imaginable.
Baseline to end of intervention (12 weeks)
Fatigue
Time Frame: Baseline to end of intervention (12 weeks)
Change in Functional Assessment of Chronic Illness Therapy - Fatigue subscale - scale is from 0-4, where 0 means "not at all" and 4 means "very much".
Baseline to end of intervention (12 weeks)
Cancer Related Quality of Life
Time Frame: Baseline to end of intervention (12 weeks)
A 5-point Likert scale (0 = not at all, to 4 = very much) to track wellbeing over the course of the cancer journey.
Baseline to end of intervention (12 weeks)
Exercise Barriers Self-Efficacy
Time Frame: Baseline to end of intervention (12 weeks)
Exercise barriers and facilitators questionnaire
Baseline to end of intervention (12 weeks)
Cognition
Time Frame: Baseline to end of intervention (12 weeks)
Cancer related cognition using the Functional Assessment of Cancer Therapy - Cognition questionnaire. A 37-item, self-report questionnaire used to evaluate how cancer patients perceive their own cognitive abilities
Baseline to end of intervention (12 weeks)
Aerobic Capacity
Time Frame: Baseline to end of intervention (12 weeks)
In-person participants will be assessed on change in 6-minute walk test (m) results
Baseline to end of intervention (12 weeks)
Aerobic Capacity
Time Frame: Baseline to end of intervention (12 weeks)
Online participants will be assessed with change in the 2-minute step test (number of steps) results.
Baseline to end of intervention (12 weeks)
Lower body strength
Time Frame: Baseline to end of intervention (12 weeks)
Change in sit-to-stand (number of repetitions in 30 seconds)
Baseline to end of intervention (12 weeks)
Upper extremity flexibility
Time Frame: Baseline to end of intervention (12 weeks)
Change in active shoulder flexion range of motion (degrees)
Baseline to end of intervention (12 weeks)
Balance
Time Frame: Baseline to end of intervention (12 weeks)
Change in one legged stance test (seconds)
Baseline to end of intervention (12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Calgary

Collaborators

Canadian Institutes of Health Research (CIHR)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2025

Primary Completion (Actual)

December 12, 2025

Study Completion (Actual)

December 12, 2025

Study Registration Dates

First Submitted

May 11, 2026

First Submitted That Met QC Criteria

June 8, 2026

First Posted (Actual)

June 11, 2026

Study Record Updates

Last Update Posted (Actual)

June 11, 2026

Last Update Submitted That Met QC Criteria

June 8, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HREBA.CC-25-0150

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Aggregate and participant-level results are reported within publications, but there is no formal plan for external IPD sharing. With a small sample size from a specific cultural group, there may be risk of re-identification.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on EXCEL-Punjabi

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe